CAR ART SIGNED
Chimeric Antigen Receptor to generate Alloantigen-specific Regulatory T cells and promote allograft tolerance
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0CAR ART project word cloud
Explore the words cloud of the CAR ART project. It provides you a very rough idea of what is the project "CAR ART" about.
Project "CAR ART" data sheet
The following table provides information about the project.
| Coordinator |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Organization address contact info |
| Coordinator Country | France [FR] |
| Total cost | 171˙349 € |
| EC max contribution | 171˙349 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2016 |
| Funding Scheme | MSCA-IF-GF |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-11-01 to 2019-10-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS | FR (PARIS) | coordinator | 171˙349.00 |
| 2 | UNIVERSITY OF BRITISH COLUMBIA | CA (VANCOUVER) | partner | 0.00 |
Map
Project objective
Organ transplantation is the best life-supporting treatment for terminal organ failure. Graft survival is however limited by rejection, a destructive process resulting from the response of recipient’s immune system against donor specific alloantigens. Prevention of rejection currently relies on immunosuppressive drugs that lack antigen specificity and therefore increase the risk for infections and cancers. Induction of donor-specific tolerance would provide indefinite graft survival without morbidity and therefore represents the Grail of transplant immunologists. Tolerance has been obtained in experimental models with adoptive transfer of ex vivo-expanded CD4FOXP3 regulatory T cells (Treg). Preclinical studies have indicated that the potency and specificity of Treg therapy could be markedly enhanced by the use of Treg specific for donor alloantigens. Translation of this approach in the clinic has been hindered by the lack of clinically applicable strategies to generate sufficient numbers of potent donor-specific Tregs. To overcome this limitation, Pr Levings’ group (Child and Family Research Institute, Vancouver, Canada) has just recently successfully used chimeric antigen receptor (CAR) technology to redirect the specificity of human Treg toward a transplant-relevant antigen. The objective of the 2-year action is to assess the impact of alloantigen-specific CAR Treg on cellular and humoral alloimmune responses and their ability to promote allograft tolerance. The outgoing phase of the global fellowship will be performed in Pr Levings’ lab, and the return phase in Pr Glaichenhaus’ team (Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France) where the researcher will get in few years a tenured position. The main ambition of the program is to provide key data for the development of a clinical trial with CAR Tregs in kidney transplantation.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAR ART" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CAR ART" are provided by the European Opendata Portal: CORDIS opendata.